,address1,address2,city,state,zip,country,phone,fax,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,forwardPE,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Harry Perkins Institute of Medical Research,6 Verdun Street,Nedlands,WA,6009,Australia,61 8 6151 0992,61 8 9315 5475,https://pyctx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.","{'maxAge': 1, 'name': 'Dr. Rohan  Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)', 'age': 39, 'title': 'CEO & Exec. Director', 'yearBorn': 1983, 'fiscalYear': 2023, 'totalPay': 437500, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.056,0.057,0.056,0.059,0.056,0.057,0.056,0.059,0.0,0.195195,211982,211982,1447188,1147886,1147886,0.056,0.059,0,0,209040720,0.05,0.098,13.225189,0.05984,0.06426,0.0,0.0,AUD,205676080,Infinity,-1.4417701,2413074631,3732869888,0.58467996,2.0000001e-05,3732869888,0.008,7.0,1688083200,1719705600,1688083200,-22788984,-0.01,0.0,13.012,-9.02,-0.21126759,0.14113986,ASX,EQUITY,PYC.AX,PYC.AX,PYC THERAP FPO,PYC Therapeutics Limited,1112140800,Australia/Sydney,AEST,fcb5cb8a-9b40-3bc3-a283-75faf24a5e61,finmb_21956839,36000000,0.056,2.0,buy,15571534,0.004,-22801012,315487,3.786,3.792,15806256,1.109,0.005,-0.35494,-0.68050003,15806256,-16403756,-24421686,0.227,1.0,-1.44253,-1.48238,AUD,
1,Harry Perkins Institute of Medical Research,6 Verdun Street,Nedlands,WA,6009,Australia,61 8 6151 0992,61 8 9315 5475,https://pyctx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.","{'maxAge': 1, 'name': 'Mr. Andrew  Taylor B.Com., C.A.', 'title': 'CFO & Company Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.056,0.057,0.056,0.059,0.056,0.057,0.056,0.059,0.0,0.195195,211982,211982,1447188,1147886,1147886,0.056,0.059,0,0,209040720,0.05,0.098,13.225189,0.05984,0.06426,0.0,0.0,AUD,205676080,Infinity,-1.4417701,2413074631,3732869888,0.58467996,2.0000001e-05,3732869888,0.008,7.0,1688083200,1719705600,1688083200,-22788984,-0.01,0.0,13.012,-9.02,-0.21126759,0.14113986,ASX,EQUITY,PYC.AX,PYC.AX,PYC THERAP FPO,PYC Therapeutics Limited,1112140800,Australia/Sydney,AEST,fcb5cb8a-9b40-3bc3-a283-75faf24a5e61,finmb_21956839,36000000,0.056,2.0,buy,15571534,0.004,-22801012,315487,3.786,3.792,15806256,1.109,0.005,-0.35494,-0.68050003,15806256,-16403756,-24421686,0.227,1.0,-1.44253,-1.48238,AUD,
2,Harry Perkins Institute of Medical Research,6 Verdun Street,Nedlands,WA,6009,Australia,61 8 6151 0992,61 8 9315 5475,https://pyctx.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.","{'maxAge': 1, 'name': 'Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA', 'age': 60, 'title': 'Company Sec.', 'yearBorn': 1962, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.056,0.057,0.056,0.059,0.056,0.057,0.056,0.059,0.0,0.195195,211982,211982,1447188,1147886,1147886,0.056,0.059,0,0,209040720,0.05,0.098,13.225189,0.05984,0.06426,0.0,0.0,AUD,205676080,Infinity,-1.4417701,2413074631,3732869888,0.58467996,2.0000001e-05,3732869888,0.008,7.0,1688083200,1719705600,1688083200,-22788984,-0.01,0.0,13.012,-9.02,-0.21126759,0.14113986,ASX,EQUITY,PYC.AX,PYC.AX,PYC THERAP FPO,PYC Therapeutics Limited,1112140800,Australia/Sydney,AEST,fcb5cb8a-9b40-3bc3-a283-75faf24a5e61,finmb_21956839,36000000,0.056,2.0,buy,15571534,0.004,-22801012,315487,3.786,3.792,15806256,1.109,0.005,-0.35494,-0.68050003,15806256,-16403756,-24421686,0.227,1.0,-1.44253,-1.48238,AUD,
